We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Esophageal Cancer in Relative Increases Barrett’s Risk

By LabMedica International staff writers
Posted on 09 Nov 2017
Barrett's esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the esophagus. More...
It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by simple columnar epithelium with goblet cells.

While it is well known that esophageal adenocarcinoma is a common complication of Barrett’s esophagus, the significance of family history of esophageal adenocarcinoma in disease progression among patients with Barrett’s esophagus is not well-known. Patients with Barrett’s esophagus who have a first-degree relative with esophageal adenocarcinoma are at 5.5-fold increased risk for progression to esophageal adenocarcinoma.

Scientists at Thomas Jefferson University Hospital (Philadelphia, PA, USA) conducted a retrospective cohort study including 301 patients with Barrett’s esophagus undergoing radiofrequency ablation at a tertiary care center. The investigators pooled data from electronic medical records on patient age, sex, age at diagnosis of Barrett’s esophagus and esophageal adenocarcinoma, pathology and length of Barrett’s esophagus segment. They assessed information on family history in all patients, including those with and without esophageal adenocarcinoma.

The team excluded from the study 19 patients with intramucosal adenocarcinoma on index endoscopy. Overall, 6.7% of patients with Barrett’s esophagus had a first-degree relative with a history of esophageal adenocarcinoma. Of these, 21.1% had disease that progressed to esophageal adenocarcinoma compared with 8.7% of patients without a first-degree relative with esophageal adenocarcinoma. After adjusting for sex and the number of radiofrequency ablation treatments, they found that family history of esophageal adenocarcinoma was a significant independent predictor for progression to adenocarcinoma (OR=5.55; 95% CI, 1.47-20).

Christina J. Tofani, MD, a gastroenterologist and lead author of the study, said, “Our study suggests that family history of esophageal adenocarcinoma is an independent risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus patients and should be carefully considered in patient surveillance and radiofrequency ablation treatment, beyond current recommended guidelines.” The study was presented at the World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting, held October 13-18, 2017, in Orlando, FL, USA.

Related Links:
Thomas Jefferson University Hospital


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.